211 related articles for article (PubMed ID: 1918882)
21. Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA).
Chazouillères O; Marteau P; Haniche M; Jian R; Poupon R
Dig Dis Sci; 1996 Dec; 41(12):2417-22. PubMed ID: 9011452
[TBL] [Abstract][Full Text] [Related]
22. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
[TBL] [Abstract][Full Text] [Related]
24. Increased intercellular adhesion molecule-1 serum concentration in cholestasis.
Polzien F; Ramadori G
J Hepatol; 1996 Dec; 25(6):877-86. PubMed ID: 9007716
[TBL] [Abstract][Full Text] [Related]
25. Effect of 6-8 weeks of oral ursodeoxycholic acid administration on serum concentrations of fasting and postprandial bile acids and biochemical analytes in healthy dogs.
Deitz KL; Makielski KM; Williams JM; Lin H; Morrison JA
Vet Clin Pathol; 2015 Sep; 44(3):431-6. PubMed ID: 26274488
[TBL] [Abstract][Full Text] [Related]
26. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
27. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.
Combes B; Carithers RL; Maddrey WC; Munoz S; Garcia-Tsao G; Bonner GF; Boyer JL; Luketic VA; Shiffman ML; Peters MG; White H; Zetterman RK; Risser R; Rossi SS; Hofmann AF
Hepatology; 1999 Jun; 29(6):1649-54. PubMed ID: 10347103
[TBL] [Abstract][Full Text] [Related]
28. The effects of ursodeoxycholic acid on serum and biliary noncholesterol sterols in patients with gallstones.
Miettinen TE; Tarpila S; Gylling H
Hepatology; 1997 Mar; 25(3):514-8. PubMed ID: 9049189
[TBL] [Abstract][Full Text] [Related]
29. 5 beta-hydroxylation by the liver. Identification of 3,5,7-trihydroxy nor-bile acids as new major biotransformation products of 3,7-dihydroxy nor-bile acids in rodents.
Schteingart CD; Hagey LR; Setchell KD; Hofmann AF
J Biol Chem; 1993 May; 268(15):11239-46. PubMed ID: 8496179
[TBL] [Abstract][Full Text] [Related]
30. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
31. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Pusl T; Beuers U
World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
[TBL] [Abstract][Full Text] [Related]
32. [Clinical significance of 3 beta, 7 beta-dihydroxy-5 beta-cholan-24-oic acid (isoUDCA) in serum during administration of ursodeoxycholic acid].
Nakamura K; Hotta H; Makino I
Nihon Shokakibyo Gakkai Zasshi; 1993 Nov; 90(11):2961. PubMed ID: 8271473
[No Abstract] [Full Text] [Related]
33. Chronic cholestatic diseases.
Poupon R; Chazouillères O; Poupon RE
J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
[TBL] [Abstract][Full Text] [Related]
34. Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III.
Lotterer E; Stiehl A; Raedsch R; Foelsch UR; Bircher J
J Hepatol; 1990 May; 10(3):284-90. PubMed ID: 2365981
[TBL] [Abstract][Full Text] [Related]
35. Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis.
Roda E; Mazzella G; Bazzoli F; Villanova N; Minutello A; Simoni P; Ronchi M; Poggi C; Festi D; Aldini R
Dig Dis Sci; 1989 Dec; 34(12 Suppl):52S-58S. PubMed ID: 2598768
[TBL] [Abstract][Full Text] [Related]
36. [Effect of ursodeoxycholic acid (UDCA) therapy for compensatory liver cirrhosis on liver function tests and serum bile acid metabolism].
Nakamura K; Aoshima M; Tani M; Kato T; Fugita M; Kimura A; Hasegawa T; Akiyama K; Makino I
Nihon Shokakibyo Gakkai Zasshi; 1992 Dec; 89(12):2762-70. PubMed ID: 1491464
[TBL] [Abstract][Full Text] [Related]
37. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
38. Identification of 3 beta, 7 beta-dihydroxy-5 beta-cholan-24-oic acid in serum from patients treated with ursodeoxycholic acid.
Maeda M; Ohama H; Takeda H; Yabe M; Nambu M; Namihisa T
J Lipid Res; 1984 Jan; 25(1):14-26. PubMed ID: 6707518
[TBL] [Abstract][Full Text] [Related]
39. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease.
Beuers U; Spengler U; Zwiebel FM; Pauletzki J; Fischer S; Paumgartner G
Hepatology; 1992 Apr; 15(4):603-8. PubMed ID: 1551637
[TBL] [Abstract][Full Text] [Related]
40. Bile acid metabolism, bacterial bowel flora and intestinal function following ileal pouch-anal anastomosis in dogs, with reference to the influence of administration of ursodeoxycholic acid.
Imamura M; Nakajima H; Takahashi H; Yamauchi H; Seo G
Tohoku J Exp Med; 2000 Feb; 190(2):103-17. PubMed ID: 10770619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
